Year Book of Oncology 2012

1. Cover image - p. 1 2. Title page - p. 2 3. Table of Contents - p. 3 4. Chapter 1. Cancer Biology - p. 8 5. Clinically Relevant Changes in Family History of Cancer Over Time - p. 8 6. Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing - p. 9 7. Chapter 2. Cancer Prevention - p. 10 8. Chapter 3. Cancer Therapies - p. 11 9. Chapter 4. Chemotherapy: Mechanisms and Side Effects - p. 12 10. Chapter 5. Breast Cancer - p. 13 11. 5.1. General Issues in Breast Cancer - p. 13 12. Characteristics and Outcomes of Breast Cancer in Women With and Without a History of Radiation for Hodgkin’s Lymphoma: A Multi-Institutional, Matched Cohort Study - p. 13 13. Quality-of-Life Measurement in Randomized Clinical Trials in Breast Cancer: An Updated Systematic Review (2001–2009) - p. 14 14. 5.2. Epidemiology - p. 15 15. 5.3. Prevention - p. 17 16. 5.4. Early Stage and Adjuvant Therapy - p. 18 17. Adjuvant Therapy in Stage I Carcinoma of the Breast: The Influence of Multigene Analyses and Molecular Phenotyping - p. 18 18. Association of Occult Metastases in Sentinel Lymph Nodes and Bone Marrow With Survival Among Women With Early-Stage Invasive Breast Cancer - p. 19 19. Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer - p. 20 20. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100000 women in 123 randomised trials - p. 21 21. Disease-Related Outcomes With Long-Term Follow-Up: An Updated Analysis of the Intergroup Exemestane Study - p. 22 22. Preoperative Chemotherapy Plus Trastuzumab, Lapatinib, or Both in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer: Results of the Randomized Phase II CHER-LOB Study - p. 23 23. Effect of Obesity on Prognosis After Early-Stage Breast Cancer - p. 24 24. Effect of Occult Metastases on Survival in Node-Negative Breast Cancer - p. 25 25. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial - p. 26 26. 5.5. Breast Conserving Therapy - p. 27 27. Ductal Carcinoma In Situ Treated With Breast-Conserving Surgery and Accelerated Partial Breast Irradiation: Comparison of the Mammosite Registry Trial With Intergroup Study E5194 - p. 27 28. Comparison of treatment outcome between breast-conservation surgery with radiation and total mastectomy without radiation in patients with one to three positive axillary lymph nodes - p. 28 29. 5.6. Diagnostic Imaging - p. 29 30. Breast Imaging Training and Attitudes: Update Survey of Senior Radiology Residents - p. 29 31. Screening Breast MR Imaging in Women with a History of Chest Irradiation - p. 30 32. 5.7. Prognostic Factors - p. 31 33. Effect of HER2 status on risk of recurrence in women with small, node-negative breast tumours - p. 31 34. Factors influencing survival in patients with breast cancer and single or solitary brain metastasis - p. 32 35. 5.8. Radiation Therapy - p. 34 36. Accelerated partial breast irradiation with interstitial implants: risk factors associated with increased local recurrence - p. 34 37. Accelerated partial breast irradiation: 5-year results of the German-Austrian multicenter phase II trial using interstitial multicatheter brachytherapy alone after breast-conserving surgery - p. 35 38. Age, Comorbidity, and Breast Cancer Severity: Impact on Receipt of Definitive Local Therapy and Rate of Recurrence among Older Women with Early-Stage Breast Cancer - p. 36 39. Early-stage young breast cancer patients: Impact of local treatment on survival - p. 37 40. Fractionation for whole breast irradiation: An American Society for Radiation Oncology (ASTRO) evidence-based guideline - p. 38 41. Irradiation effect after mastectomy on breast cancer recurrence in patients presenting with locally advanced disease - p. 40 42. 5.9. Surgical Treatment - p. 41 43. Liver resection and local ablation of breast cancer liver metastases – A systematic review - p. 41 44. Phase III randomized equivalence trial of early breast cancer treatments with or without axillary clearance in post-menopausal patients results after 5 years of follow-up - p. 42 45. Subsets of women with close or positive margins after breast-conserving surgery with high local recurrence risk despite breast plus boost radiotherapy - p. 45 46. 5.10. Tumor Biology - p. 48 47. 5.11. Axillary Management - p. 49 48. 5.12. Hormonal Therapy - p. 50 49. 5.13. Intraductal Cancer - p. 52 50. 5.14. Non-Invasive Cancer - p. 53 51. 5.15. Advanced - p. 54 52. Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer - p. 54 53. Loss of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Metastatic Sites of HER2-Overexpressing Primary Breast Tumors - p. 55 54. Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer - p. 56 55. 5.16. Miscellaneous - p. 57 56. Management of hot flashes in patients who have breast cancer with venlafaxine and clonidine: a randomized, double-blind, placebo-controlled trial - p. 57 57. Nodal status and clinical outcomes in a large cohort of patients with triple-negative breast cancer - p. 58 58. Chapter 6. Genitourinary - p. 59 59. 6.1. Prostate - p. 59 60. 10-year experience with I-125 prostate brachytherapy at the Princess Margaret Hospital: results for 1,100 patients - p. 59 61. American Society for Radiation Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the transperineal permanent brachytherapy of prostate cancer - p. 60 62. Behavioral Therapy With or Without Biofeedback and Pelvic Floor Electrical Stimulation for Persistent Postprostatectomy Incontinence: A Randomized Controlled Trial - p. 61 63. Comparison of Health-Related Quality of Life 5 Years After SPIRIT: Surgical Prostatectomy Versus Interstitial Radiation Intervention Trial - p. 62 64. Cost-Effectiveness of Prostate Specific Antigen Screening in the United States: Extrapolating From the European Study of Screening for Prostate Cancer - p. 63 65. Definition of medical event is to be based on the total source strength for evaluation of permanent prostate brachytherapy: A report from the American Society for Radiation Oncology - p. 64 66. Does hormone therapy reduce disease recurrence in prostate cancer patients receiving dose-escalated radiation therapy? An analysis of Radiation Therapy Oncology Group 94-06 - p. 65 67. Dose escalation and quality of life in patients with localized prostate cancer treated with radiotherapy: long-term results of the Dutch randomized dose-escalation trial (CKTO 96-10 Trial) - p. 66 68. Fifteen-year biochemical relapse-free survival, cause-specific survival, and overall survival following I125 prostate brachytherapy in clinically localized prostate cancers: Seattle experience - p. 67 69. Phase I dose-escalation study of stereotactic body radiation therapy for low and intermediate-risk prostate cancer - p. 68 70. Progression From High-Grade Prostatic Intraepithelial Neoplasia to Cancer: A Randomized Trial of Combination Vitamin-E, Soy, and Selenium - p. 69 71. Radiotherapy and Short-Term Androgen Deprivation for Localized Prostate Cancer - p. 70 72. Radical Prostatectomy versus Watchful Waiting in Early Prostate Cancer - p. 71 73. Vitamin E and the Risk of Prostate Cancer: The Selenium and Vitamin E Cancer Prevention Trial (SELECT) - p. 72 74. 6.2. Testis - p. 73 75. Association of diagnostic radiation exposure and second abdominal-pelvic malignancies after testicular cancer - p. 73 76. Management of Seminomatous Testicular Cancer: A Binational Prospective Population-Based Study From the Swedish Norwegian Testicular Cancer Study Group - p. 74 77. Randomized Trial of Carboplatin Versus Radiotherapy for Stage I Seminoma: Mature Results on Relapse and Contralateral Testis Cancer Rates in MRC TE19/EORTC 30982 Study (ISRCTN27163214) - p. 75 78. Chapter 7. Gynecology - p. 76 79. 7.1. Ovarian - p. 76 80. A Multicenter, Randomized, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of Combination Docetaxel and Carboplatin and Sequential Therapy With Docetaxel Then Carboplatin in Patients With Recurrent Platinum-Sensitive Ovarian Cancer - p. 76 81. A Phase 3 Trial of Bevacizumab in Ovarian Cancer - p. 77 82. A systematic review evaluating the relationship between progression free survival and post progression survival in advanced ovarian cancer - p. 78 83. CA-125 can be part of the tumour evaluation criteria in ovarian cancer trials: experience of the GCIG CALYPSO trial - p. 79 84. Evolution of surgical treatment paradigms for advanced-stage ovarian cancer: Redefining ‘optimal’ residual disease - p. 80 85. Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients - p. 81 86. Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer - p. 82 87. Is comprehensive surgical staging needed for thorough evaluation of early-stage ovarian carcinoma? - p. 83 88. OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer - p. 84 89. Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer - p. 85 90. Ovarian low-grade serous carcinoma: A comprehensive update - p. 86 91. Phase II, Open-Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of Olaparib, a Poly (ADP-Ribose) Polymerase Inhibitor, and Pegylated Liposomal Doxorubicin in Patients With BRCA1 or BRCA2 Mutations and Recurrent Ovarian Cancer - p. 87 92. Randomized, Double-Blind, Placebo-Controlled Phase II Study of AMG 386 Combined With Weekly Paclitaxel in Patients With Recurrent Ovarian Cancer - p. 88 93. Reclassification of Serous Ovarian Carcinoma by a 2-Tier System: A Gynecologic Oncology Group Study - p. 89 94. Vignette-Based Study of Ovarian Cancer Screening: Do U.S. Physicians Report Adhering to Evidence-Based Recommendations? - p. 90 95. 7.2. Cervix - p. 91 96. A multi-institutional phase II trial of paclitaxel and carboplatin in the treatment of advanced or recurrent cervical cancer - p. 91 97. Chemoradiation and adjuvant chemotherapy in advanced cervical adenocarcinoma - p. 92 98. Comparison of treatment outcomes between squamous cell carcinoma and adenocarcinoma in locally advanced cervical cancer - p. 93 99. Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy for the definitive treatment of cervix cancer - p. 94 100. Management of recurrent cervical cancer: A review of the literature - p. 95 101. 7.3. Endometrial - p. 96 102. Association of number of positive nodes and cervical stroma invasion with outcome of advanced endometrial cancer treated with chemotherapy or whole abdominal irradiation: A Gynecologic Oncology Group study - p. 96 103. Metformin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and modulation of the mTOR pathway - p. 97 104. Recurrence and Survival After Random Assignment to Laparoscopy Versus Laparotomy for Comprehensive Surgical Staging of Uterine Cancer: Gynecologic Oncology Group LAP2 Study - p. 98 105. The role of lymphadenectomy in endometrial cancer: Was the ASTEC trial doomed by design and are we destined to repeat that mistake? - p. 99 106. 7.4. Miscellaneous - p. 100 107. Chapter 8. Gastrointestinal - p. 101 108. 8.1. Screening and Detection - p. 101 109. 8.2. Esophagus, Stomach - p. 102 110. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial - p. 102 111. Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study - p. 103 112. Salvage Chemotherapy for Pretreated Gastric Cancer: A Randomized Phase III Trial Comparing Chemotherapy Plus Best Supportive Care With Best Supportive Care Alone - p. 104 113. 8.3. Pancreas - p. 105 114. 8.4. Rectal Carcinoma - p. 106 115. A Phase II Trial of Neoadjuvant Chemoradiation and Local Excision for T2N0 Rectal Cancer: Preliminary Results of the ACOSOG Z6041 Trial - p. 106 116. Primary Tumor Response to Preoperative Chemoradiation With or Without Oxaliplatin in Locally Advanced Rectal Cancer: Pathologic Results of the STAR-01 Randomized Phase III Trial - p. 107 117. 8.5. Colorectal Cancer - p. 108 118. Chapter 9. Hematologic Malignancies - p. 109 119. 9.1. Leukemia and Myelodysplastic Syndrome - p. 109 120. Clonal origins of relapse in ETV6-RUNX1 acute lymphoblastic leukemia - p. 109 121. Radiation therapy for leukemia cutis - p. 110 122. The genetic basis of early T–cell precursor acute lymphoblastic leukaemia - p. 111 123. TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome - p. 112 124. A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia - p. 113 125. Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007 - p. 114 126. Age-Related Prognostic Impact of Different Types of DNMT3A Mutations in Adults With Primary Cytogenetically Normal Acute Myeloid Leukemia - p. 115 127. Assessment of BCR-ABL1 Transcript Levels at 3 Months Is the Only Requirement for Predicting Outcome for Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors - p. 116 128. Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival - p. 117 129. DNMT3A mutations in acute myeloid leukemia: stability during disease evolution and clinical implications - p. 118 130. Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes - p. 119 131. Increased BMI correlates with higher risk of disease relapse and differentiation syndrome in patients with acute promyelocytic leukemia treated with the AIDA protocols - p. 120 132. Outcomes after matched unrelated donor versus identical sibling hematopoietic cell transplantation in adults with acute myelogenous leukemia - p. 121 133. Pediatric-inspired intensified therapy of adult T-ALL reveals the favorable outcome of NOTCH1/FBXW7 mutations, but not of low ERG/BAALC expression: a GRAALL study - p. 122 134. Poor response to second-line kinase inhibitors in chronic myeloid leukemia patients with multiple low-level mutations, irrespective of their resistance profile - p. 123 135. Prediction of Early Death After Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia With Pretreatment Risk Scores: A Novel Paradigm for Treatment Assignment - p. 124 136. Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia - p. 125 137. Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia - p. 126 138. 9.2. Lymphoma - p. 127 139. Chapter 10. Thoracic Cancer - p. 128 140. 10.1. Biology - p. 128 141. DNA Repair Capacity in Peripheral Lymphocytes Predicts Survival of Patients With Non–Small-Cell Lung Cancer Treated With First-Line Platinum-Based Chemotherapy - p. 128 142. Genetic Variations and Patient-Reported Quality of Life Among Patients With Lung Cancer - p. 129 143. 10.2. Non Small Cell: Early Stage and Adjuvant Therapy - p. 130 144. Occult metastases in lymph nodes predict survival in resectable non–small-cell lung cancer: report of the ACOSOG Z0040 trial - p. 130 145. Phase III Comparison of Prophylactic Cranial Irradiation Versus Observation in Patients With Locally Advanced Non–Small-Cell Lung Cancer: Primary Analysis of Radiation Therapy Oncology Group Study RTOG 0214 - p. 131 146. Randomized Phase III Study of Surgery Alone or Surgery Plus Preoperative Cisplatin and Gemcitabine in Stages IB to IIIA Non–Small-Cell Lung Cancer - p. 132 147. Randomized Phase III Study of Thoracic Radiation in Combination With Paclitaxel and Carboplatin With or Without Thalidomide in Patients With Stage III Non–Small-Cell Lung Cancer: The ECOG 3598 Study - p. 133 148. Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening - p. 134 149. 10.3. First Line Metastatic Non-Small Cell Lung Cancer - p. 135 150. First-SIGNAL: First-Line Single-Agent Iressa Versus Gemcitabine and Cisplatin Trial in Never-Smokers With Adenocarcinoma of the Lung - p. 135 151. Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor EGFR mutations - p. 136 152. Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study - p. 137 153. Prospective Molecular Marker Analyses of EGFR and KRAS From a Randomized, Placebo-Controlled Study of Erlotinib Maintenance Therapy in Advanced Non–Small-Cell Lung Cancer - p. 138 154. Randomized Phase II Trial of Erlotinib Alone or With Carboplatin and Paclitaxel in Patients Who Were Never or Light Former Smokers With Advanced Lung Adenocarcinoma: CALGB 30406 Trial - p. 139 155. Randomized, Double-Blind, Placebo-Controlled Phase II Study of Single-Agent Oral Talactoferrin in Patients With Locally Advanced or Metastatic Non–Small-Cell Lung Cancer That Progressed After Chemotherapy - p. 140 156. Weekly nab-Paclitaxel in Combination With Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Final Results of a Phase III Trial - p. 141 157. 10.4. Second Line Metastatic Non-Small Cell Lung Cancer - p. 142 158. Sunitinib Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer: A Phase III Trial - p. 142 159. Vandetanib Versus Placebo in Patients With Advanced Non–Small-Cell Lung Cancer After Prior Therapy With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor: A Randomized, Double-Blind Phase III Trial (ZEPHYR) - p. 143 160. 10.5. Small Cell Lung Cancer - p. 144 161. Carboplatin- or Cisplatin-Based Chemotherapy in First-Line Treatment of Small-Cell Lung Cancer: The COCIS Meta-Analysis of Individual Patient Data - p. 144 162. Cisplatin, Irinotecan, and Bevacizumab for Untreated Extensive-Stage Small-Cell Lung Cancer: CALGB 30306, a Phase II Study - p. 145 163. 10.6. Advanced Diseases - p. 146 164. Randomized Phase II Study of Dulanermin in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Advanced Non–Small-Cell Lung Cancer - p. 146 165. Randomized Phase II Study of Erlotinib in Combination With Placebo or R1507, a Monoclonal Antibody to Insulin-Like Growth Factor-1 Receptor, for Advanced-Stage Non–Small-Cell Lung Cancer - p. 147 166. Randomized, Placebo-Controlled Phase III Study of Docetaxel Plus Carboplatin With Celecoxib and Cyclooxygenase-2 Expression as a Biomarker for Patients With Advanced Non–Small-Cell Lung Cancer: the NVALT-4 Study - p. 148 167. 10.7. Miscellaneous - p. 149 168. Longitudinal Perceptions of Prognosis and Goals of Therapy in Patients With Metastatic Non–Small-Cell Lung Cancer: Results of a Randomized Study of Early Palliative Care - p. 149 169. ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers - p. 150 170. Chapter 11. Endocrine - p. 151 171. Chapter 12. Head and Neck - p. 152 172. A Phase 2 Trial of Bortezomib Followed by the Addition of Doxorubicin at Progression in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma of the Head and Neck: A trial of the Eastern Cooperative Oncology Group (E1303) - p. 152 173. A prospective, comparative study on the early effects of local and remote radiation therapy on carotid intima–media thickness and vascular cellular adhesion molecule-1 in patients with head and neck and prostate tumors - p. 153 174. Chapter 13. Pediatric Cancer - p. 154 175. 13.1. Leukemia - p. 154 176. Anti–Escherichia coli asparaginase antibody levels determine the activity of second-line treatment with pegylated E coli asparaginase: a retrospective analysis within the ALL-BFM trials - p. 154 177. Developmental origins and impact of BCR-ABL1 fusion and IKZF1 deletions in monozygotic twins with Ph+ acute lymphoblastic leukemia - p. 155 178. Improved Survival for Children and Adolescents With Acute Lymphoblastic Leukemia Between 1990 and 2005: A Report From the Children’s Oncology Group - p. 156 179. Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children’s Oncology Group Study - p. 157 180. Outcomes after Induction Failure in Childhood Acute Lymphoblastic Leukemia - p. 158 181. 13.2. Neuro-Oncology - p. 159 182. Clonal selection drives genetic divergence of metastatic medulloblastoma - p. 159 183. Genome-Wide Analyses Identify Recurrent Amplifications of Receptor Tyrosine Kinases and Cell-Cycle Regulatory Genes in Diffuse Intrinsic Pontine Glioma - p. 160 184. Pre-Enucleation Chemotherapy for Eyes Severely Affected by Retinoblastoma Masks Risk of Tumor Extension and Increases Death From Metastasis - p. 161 185. 13.3. Solid Tumors - p. 162 186. Clinical and Biologic Features Predictive of Survival After Relapse of Neuroblastoma: A Report From the International Neuroblastoma Risk Group Project - p. 162 187. Outcome After Surgery Alone or With Restricted Use of Chemotherapy for Patients With Low-Risk Neuroblastoma: Results of Children’s Oncology Group Study P9641 - p. 163 188. PAX3/FOXO1 Fusion Gene Status Is the Key Prognostic Molecular Marker in Rhabdomyosarcoma and Significantly Improves Current Risk Stratification - p. 164 189. Pilot Induction Regimen Incorporating Pharmacokinetically Guided Topotecan for Treatment of Newly Diagnosed High-Risk Neuroblastoma: A Children’s Oncology Group Study - p. 165 190. Prognostic Significance and Tumor Biology of Regional Lymph Node Disease in Patients With Rhabdomyosarcoma: A Report From the Children’s Oncology Group - p. 166 191. 13.4. Miscellaneous - p. 167 192. Chapter 14. Melanoma - p. 168 193. Chapter 15. Sarcoma - p. 169 194. Chapter 16. Late Effects of Therapy - p. 170 195. Anthracycline-Related Cardiomyopathy After Childhood Cancer: Role of Polymorphisms in Carbonyl Reductase Genes—A Report From the Children’s Oncology Group - p. 170 196. Congenital Anomalies in the Children of Cancer Survivors: A Report From the Childhood Cancer Survivor Study - p. 171 197. Nonmalignant Late Effects and Compromised Functional Status in Survivors of Hematopoietic Cell Transplantation - p. 172 198. Pharmacogenomic Prediction of Anthracycline-Induced Cardiotoxicity in Children - p. 173 199. Secondary solid cancers after allogeneic hematopoietic cell transplantation using busulfan-cyclophosphamide conditioning - p. 174 200. Chapter 17. Novel Targets - p. 175 201. Chapter 18. Supportive Care - p. 176 202. Impact of Awareness of Terminal Illness and Use of Palliative Care or Intensive Care Unit on the Survival of Terminally Ill Patients With Cancer: Prospective Cohort Study - p. 176 203. Semuloparin for Thromboprophylaxis in Patients Receiving Chemotherapy for Cancer - p. 177 204. Chapter 19. Miscellaneous - p. 178